Search research articles
Contact Us
Filters
Showing results (1-10 of 175) with videos related to
Page
of 18
Sort By:
Drug Discovery Today
|
September 27, 2016
The challenges of modulating the 'rest and digest' system: acetylcholine receptors as drug targets
Sonya VanPatten, Yousef Al-Abed
Future Medicinal Chemistry
|
March 25, 2011
MIF as a disease target: ISO-1 as a proof-of-concept therapeutic
Yousef Al-Abed, Sonya VanPatten
Journal of Neuroinflammation
|
January 23, 2014
MIF: mood improving/inhibiting factor?
Joshua Bloom, Yousef Al-Abed
Journal of Medicinal Chemistry
|
December 22, 2017
High Mobility Group Box-1 (HMGb1): Current Wisdom and Advancement as a Potential Drug Target
Sonya VanPatten, Yousef Al-Abed
Bioorganic & Medicinal Chemistry Letters
|
May 10, 2006
Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity
Kai Fan Cheng, Yousef Al-Abed
Expert Opinion on Therapeutic Targets
|
November 2, 2016
MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development
Joshua Bloom, Shan Sun, Yousef Al-Abed
Journal of Biomolecular Structure & Dynamics
|
September 22, 2018
Mechanistic insights into high mobility group box-1 (HMGb1)-induced Toll-like receptor 4 (TLR4) dimer formation
Shan Sun, Mingzhu He, Sonya VanPatten, et al.
Journal of Neuroinflammation
|
April 19, 2015
Rodent models of neuroinflammation for Alzheimer's disease
Amir Nazem, Roman Sankowski, Michael Bacher, et al.
Current Medicinal Chemistry
|
May 11, 2022
Azapeptides -A History of Synthetic Milestones and Key Examples
Kai Fan Cheng, Sonya VanPatten, Mingzhu He, et al.
Molecular Medicine (Cambridge, Mass.)
|
November 10, 2020
SARS-CoV-2 and interferon blockade
Betty Diamond, Bruce T Volpe, Sonya VanPatten, et al.
Page
of 18
Search research articles
Search
Showing results (1-10 of 175) with videos related to
Sort By:
Page
of 18
Drug Discovery Today
|
September 27, 2016
The challenges of modulating the 'rest and digest' system: acetylcholine receptors as drug targets
Sonya VanPatten, Yousef Al-Abed
Future Medicinal Chemistry
|
March 25, 2011
MIF as a disease target: ISO-1 as a proof-of-concept therapeutic
Yousef Al-Abed, Sonya VanPatten
Journal of Neuroinflammation
|
January 23, 2014
MIF: mood improving/inhibiting factor?
Joshua Bloom, Yousef Al-Abed
Journal of Medicinal Chemistry
|
December 22, 2017
High Mobility Group Box-1 (HMGb1): Current Wisdom and Advancement as a Potential Drug Target
Sonya VanPatten, Yousef Al-Abed
Bioorganic & Medicinal Chemistry Letters
|
May 10, 2006
Critical modifications of the ISO-1 scaffold improve its potent inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity
Kai Fan Cheng, Yousef Al-Abed
Expert Opinion on Therapeutic Targets
|
November 2, 2016
MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development
Joshua Bloom, Shan Sun, Yousef Al-Abed
Journal of Biomolecular Structure & Dynamics
|
September 22, 2018
Mechanistic insights into high mobility group box-1 (HMGb1)-induced Toll-like receptor 4 (TLR4) dimer formation
Shan Sun, Mingzhu He, Sonya VanPatten, et al.
Journal of Neuroinflammation
|
April 19, 2015
Rodent models of neuroinflammation for Alzheimer's disease
Amir Nazem, Roman Sankowski, Michael Bacher, et al.
Current Medicinal Chemistry
|
May 11, 2022
Azapeptides -A History of Synthetic Milestones and Key Examples
Kai Fan Cheng, Sonya VanPatten, Mingzhu He, et al.
Molecular Medicine (Cambridge, Mass.)
|
November 10, 2020
SARS-CoV-2 and interferon blockade
Betty Diamond, Bruce T Volpe, Sonya VanPatten, et al.
Page
of 18